[ad_1]
In the IMpower010 study, Tecentriq was used in comparison with best supportive care (BSC) in patients with a certain form of lung cancer, the company announced Monday.
The goal was to prolong the disease-free survival of these patients. As a first interim analysis shows, Tecentriq has resulted in a statistically significant improvement in disease-free survival (DFS).
The drug was used as adjunctive therapy after surgery and chemotherapy in patients with stage II-IIIA non-small cell lung cancer (NSCLC). According to the communication, the degree of disease-free survival was particularly pronounced in the PD-L1 positive population.
“With these groundbreaking results, Tecentriq is the first cancer immunotherapy that helps many people with resectable early-stage lung cancer live longer without the cancer coming back,” said Levi Garraway, Roche’s chief medical officer and chief development officer. of global products cited.
Roche vouchers increasingly seek study data
The pharmaceutical company Roche has achieved the objectives set with its immunotherapeutic Tecentriq in a study that is relevant for its approval. Treatment with the Roche product led to a statistically significant improvement in disease-free survival in lung cancer patients. Analysts react positively across the board, as this indication alone could generate sales of more than a billion.
At around 9.55am, Roche coupons increased 1.4 percent to CHF 312.55. His balance since the beginning of the year is positive again.
In their first comments, the experts mainly point to the potential for great success that this market offers. In addition, with this initial data, Roche also created a time advantage over the competition. Because Merck is also expected with data in this indication, according to Jefferies, for example.
“Today’s news is good news for patients, but also good news for Roche, as this indication could have potential for blockbuster,” sums up Vontobel analyst Stefan Schneider. So far, it has assumed that Roche would have to continue this study until it is completed in 2022 before it can be submitted to regulatory authorities. The Basler would have lost the competition. This is clearly not the case, as Roche has announced that it will initiate approval discussions with the highest authorities.
hr / ra
Basel (awp)
